12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Allovectin velimogene aliplasmid: Additional Phase III data

Additional data from the single-blind, international Phase III AIMM trial in 390 chemotherapy-naïve patients with recurrent stage III or IV metastatic melanoma showed that 2 mg intralesional Allovectin led to an ORR at >=24 weeks, the primary endpoint, of 5% vs. 14.6% for standard chemotherapy consisting...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >